Fujimoto K, Yasue H, Hashida S, Nakao K, Ishikawa E, Miyamoto E
Division of Cardiology, Kumamoto University School of Medicine, Japan.
Biochem Biophys Res Commun. 1995 Feb 6;207(1):75-9. doi: 10.1006/bbrc.1995.1155.
We established an enzyme immunoassay (EIA) for atrial myosin light chain 1 (ALC1) using monoclonal antibodies KA1 and KB1, which were specific for ALC1 and for both ALC1 and ventricular myosin light chain 1, respectively. The serum ALC1 levels of healthy subjects were 0.28 +/- 0.14 ng/ml (mean +/- SD). The tissue ALC1 levels of normal adult human atria were much higher than those of ventricles (p < 0.01, 2,120 +/- 1,200 in right atria, 2,180 +/- 1,450 in left atria vs. 36.0 +/- 20.2 in right ventricles, 37.7 +/- 15.3 in left ventricles, ng/mg of proteins). The tissue ALC1 levels of ventricular aneurysms were significantly higher than those of normal ventricles (p < 0.01, 206.7 +/- 101.8). These results indicate that ALC1 is augmented in aneurysms and that the EIA provides a useful tool to investigate the roles of ALC1.
我们使用单克隆抗体KA1和KB1建立了一种用于检测心房肌球蛋白轻链1（ALC1）的酶免疫测定法（EIA），这两种抗体分别对ALC1以及对ALC1和心室肌球蛋白轻链1均具有特异性。健康受试者的血清ALC1水平为0.28±0.14 ng/ml（平均值±标准差）。正常成年人心房的组织ALC1水平远高于心室（p<0.01，右心房为2,120±1,200，左心房为2,180±1,450，而右心室为36.0±20.2，左心室为37.7±15.3，ng/mg蛋白质）。室壁瘤的组织ALC1水平显著高于正常心室（p<0.01，为206.7±101.8）。这些结果表明，ALC1在瘤体中增加，并且该酶免疫测定法为研究ALC1的作用提供了一种有用的工具。
